Douglas McCloskey obtained his PhD in 2017 in bioengineering at the University of California, San Diego and was awarded the prestigious Siebel’s Scholars Foundation grant for his work in using Systems Biology approaches to reveal how metabolism drives evolution. DM was a principal investigator (PI) at the Technical University of Denmark from 2018 to 2021, where he led a group of automation engineers, software engineers, and algorithm researchers to automate the design-build-test-analyse cycle for iterative development of cell factories and new therapies. DM was Chief Scientific Officer and co-founder at AliveX Biotech from 2021 to 2022, where he led the development of an advanced AI and Omics systems immunology platform for the identification of biomarkers and drug targets for drug discovery and patient stratification for clinical translation. DM is currently a PI for a moonshot grant sponsored by and in partnership with Sanofi at the BioMed X institute, where he is leading a group of algorithm researchers to develop a virtual patient foundation model to predict clinical efficacy of drug assets.
